Niki BioSolutions (APM) Form 3 names President & COO, no trades reported

Rhea-AI Filing Summary

Niki BioSolutions, Inc. submitted a Form 3 identifying Alidad Mireskandari as the company’s President & Chief Operating Officer and reporting him as an officer, not a ten percent owner. The report does not list any insider stock transactions or any current share or option holdings for him.

Key Figures

Reported insider transactions: 0 Reported holding entries: 0

2 metrics

Reported insider transactions 0 Buy, sell, acquire, dispose, or derivative transactions for Alidad Mireskandari on this Form 3

Reported holding entries 0 Security holding entries listed for Alidad Mireskandari in the Form 3 data

Key Terms

Form 3, President & Chief Operating Officer, ten percent owner

3 terms

Form 3 regulatory

"submitted a Form 3 identifying Alidad Mireskandari as the company’s President"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

President & Chief Operating Officer regulatory

"identifying Alidad Mireskandari as the company’s President & Chief Operating Officer"

ten percent owner regulatory

"reporting him as an officer, not a ten percent owner"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/28/2026 - 05:03 PM Accepted by SEC EDGAR 07/28/2026 - 05:03 PM Learn about SEC filing dates

FAQ

What does this Form 3 mean for investors following ticker APM?

It shows that Alidad Mireskandari serves as President & COO of Niki BioSolutions, Inc. and is reported as an officer, not a ten percent owner, with no insider stock transactions or holdings disclosed in this report.

Who is the insider reported on this Niki BioSolutions, Inc. Form 3 related to APM?

The report identifies Alidad Mireskandari as the insider, serving as President & Chief Operating Officer of Niki BioSolutions, Inc. He is listed as an officer of the issuer but not as a ten percent owner in this Form 3.

Does the Niki BioSolutions, Inc. Form 3 disclose any share ownership for the insider?

No. The Form 3 for Niki BioSolutions, Inc. does not list any common stock or derivative security holdings for Alidad Mireskandari, and there are no holding entries or derivative positions reported in the data provided.

Are any insider stock trades by Alidad Mireskandari reported in this Form 3 for APM?

No insider trades are shown. The summary fields indicate zero buy, sell, acquire, dispose, or derivative transactions for Alidad Mireskandari on this Form 3, so no market activity is reported for him here.

Is Alidad Mireskandari reported as a ten percent owner of Niki BioSolutions, Inc.?

He is not reported as a ten percent owner. The officer details flag him as President & COO and explicitly indicate he is not a ten percent owner, meaning he is disclosed only in his capacity as an executive officer.

What executive role is disclosed for the insider in this Niki BioSolutions Form 3?

The report lists Alidad Mireskandari as President & Chief Operating Officer of Niki BioSolutions, Inc. This confirms his status as an executive officer of the issuer, which triggers the requirement to file an initial Form 3 ownership report.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mireskandari Alidad

(Last) (First) (Middle)

C/O NIKI BIOSOLUTIONS, INC.

116 VILLAGE BOULEVARD, SUITE 200

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/20/2026

3. Issuer Name and Ticker or Trading Symbol
Niki BioSolutions, Inc. [ NIKI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, & COO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Alidad Mireskandari	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)